Danaoprevir is indicated for the treatment of Hepatitis C, Chronic. Danoprevir was developed by Intermune Inc..
The API has now reached off-patent status, after being launched in 2018.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Danoprevir and many others, contact info@pharmacheminvestor.com